Triomics, an AI platform for oncologists, raised $22 million in Series B funding led by Battery Ventures. The startup builds tools to automate data-intensive tasks like clinical trial matching and appointment preparation. Founded in 2021, Triomics previously secured $15 million in Series A funding mid-2024.

Cancer breakthroughs extend patient lifespans but create complex medical records with thousands of pages. Triomics addresses this by providing verifiable patient summaries directly in clinical tools, reducing administrative burden. Its oncology-specific models distinguish it from generic AI, attracting institutions like Memorial Sloan Kettering and Yale Cancer Center.

The company competes with AI medical scribes like Abridge and Microsoft's Nuance. Triomics expanded its enterprise customer base fourfold over the past year, driving a tenfold increase in annualized recurring revenue. This growth underscores the significant market demand for specialized AI solutions in oncology care.